Drug Trial Radar · NCT02877264
A Study to Compare the Oral Bioavailability of Single Doses of Three Vapendavir Drug Formulations in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Nov 26, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Jun 2016
Primary completion
Aug 2016
Sponsor
- Lead sponsor
- Aviragen TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Aug 24, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Who can join
- All sexes, from 19 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, single-center, open-label, three-period, six-sequence, crossover, comparative study to evaluate the oral bioavailability of single doses of three vapendavir drug product formulations (the 264 mg free base tablet \[test drug\], 264 mg free base oral suspension \[test drug\], and two 132 mg phosphate salt capsules \[reference drug\]) in healthy volunteers. The study design consists of six dosing sequences. Each sequence comprises 3 periods and each subject is administered one of the three dosing formulations in the first period. A subject receives a different formulation in each of the subsequent periods, so that all subjects receive each formulation. The periods are separated by an approximate 7-day washout.
Conditions
- Healthy
Interventions
vapendavir 132 mg capsuleDrug
vapendavir 264 mg tabletDrug
vapendavir 24 mg/mL oral suspensionDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Relative oral bioavailability, as applicableTime frame: Study Day 0 - 17
- Maximum observed plasma concentration (Cmax)Time frame: Study Day 0 - 17
- Time at which Cmac was observed (Tmax)Time frame: Study Day 0 - 17
- Area under the plasma concentration time curve from time ) to the last measureable plasma concentration (AUC 0-last)Time frame: Study Day 0 - 17
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Aviragen Investigational Site
Saint Paul, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.